Figure 11.

The change in quality-of-life instruments Kings Sarcoidosis Questionnaire Lung (KSQ-L), Kings Sarcoidosis Questionnaire General Health (KSQ-GH), and Fatigue Assessment Score (FAS) after 24 weeks for three treatment regimens versus placebo. The minimal clinically important difference (MCID) for FAS and KSQ-L is 4 points while that for KSQ GH is 8 points. There was significant improvement for KSQ-L and KSQ-GH (as indicated by higher score) and significant reduction in fatigue as shown by a lower FAS. For KSQ-L and KSQ-GH, an increase in score means improvement, while for FAS, a decrease in score means improvement (* p-value <0.05) (31).